Compare BFS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | HELP |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2M | 862.2M |
| IPO Year | 1996 | 2020 |
| Metric | BFS | HELP |
|---|---|---|
| Price | $29.56 | $10.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $43.00 | $40.33 |
| AVG Volume (30 Days) | 133.2K | ★ 1.7M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 8.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $289,843,000.00 | N/A |
| Revenue This Year | $7.44 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | $58.28 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $29.06 | $3.76 |
| 52 Week High | $38.42 | $15.15 |
| Indicator | BFS | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 42.05 |
| Support Level | N/A | $4.41 |
| Resistance Level | $35.04 | $14.75 |
| Average True Range (ATR) | 0.63 | 0.81 |
| MACD | 0.07 | -0.16 |
| Stochastic Oscillator | 21.49 | 19.53 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.